Impact of first- and second-line treatment for Hodgkin’s lymphoma on the incidence of AML/MDS and NHL—experience of the German Hodgkin’s Lymphoma Study Group analyzed by a parametric model of carcinogenesis - Scholz, M.; Engert, A.; Franklin, J.; Josting, A.; Diehl, V.; Hasenclever, D.; Loeffler, M. (Annals of oncology, 2011)
Keywords: Algorithms; Antineoplastic agents; Antineoplastic Combined Chemotherapy Protocols - adverse effects; BEACOPP escalated; Biological and medical sciences; Bleomycin - adverse effects; carcinogenesis model; Cyclophosphamide - adverse effects; Dacarbazine - adverse effects; Doxorubicin - adverse effects; Etoposide - adverse effects; Glyoxal - adverse effects; Hematologic and hematopoietic diseases; Hodgkin Disease - drug therapy; Hodgkin Disease - mortality; Hodgkin Disease - radiotherapy; Hodgkin's lymphoma; Humans; Ifosfamide - adverse effects; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute - chemically induced; Leukemia, Myeloid, Acute - mortality; Leukemia, Myeloid, Acute - prevention & control; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Lymphoma, Non-Hodgkin - chemically induced; Lymphoma, Non-Hodgkin - mortality; Lymphoma, Non-Hodgkin - prevention & control; Medical sciences; Myelodysplastic Syndromes - chemically induced; Myelodysplastic Syndromes - mortality; Myelodysplastic Syndromes - prevention & control; Neoplasms, Second Primary - chemically induced; Neoplasms, Second Primary - mortality; Neoplasms, Second Primary - prevention & control; Pharmacology. Drug treatments; Prednimustine - adverse effects; Prednisone - adverse effects; Procarbazine - adverse effects; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk Assessment; secondary AML/MDS; secondary NHL; Treatment Outcome; Vinblastine - adverse effects; Vincristine - adverse effects; Europe; Germany; BEACOPP escalated; secondary NHL; secondary AML/MDS; carcinogenesis model; Hodgkin's lymphoma; Acute myelogenous leukemia; Secondary; Hodgkin disease; Malignant hemopathy; Non Hodgkin lymphoma; Carcinogenesis; Epidemiology; Myelodysplastic syndrome; Incidence; First line treatment; Lymphoproliferative syndrome; Second line treatment; Models; Cancer